V. Ludovini

发表

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Vienna Ludovini, Lucio Crinò, 2016, Clinical Cancer Research.

A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments

P. Valigi, L. Crinò, M. Tonato, 2006 .

Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer

R. Chiari, V. Ludovini, M. L. Belladonna, 2021, International journal of molecular sciences.

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

L. Crinò, M. Tonato, V. Ludovini, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis

L. Crinò, R. Chiari, V. Ludovini, 2016, Oncotarget.

Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer

I. Floriani, V. Ludovini, A. Corti, 2007, Cancer.

The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer.

M. Tonato, V. Ludovini, A. Cavaliere, 2003, Lung cancer.

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation

L. Crinò, R. Chiari, C. Bennati, 2011, Cancer Chemotherapy and Pharmacology.

Variations in gene expression of lung macromolecules after induction chemotherapy for lung cancer†

V. Ludovini, L. Marinucci, J. Vannucci, 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

P. Visca, L. Crinò, V. Ludovini, 2014, Journal of Translational Medicine.

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’

E. Petricoin, P. Valigi, L. Crinò, 2016, BMC Systems Biology.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

G. Botti, D. Galetta, L. Crinò, 2019, Cancers.

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

L. Crinò, V. Ludovini, G. Servillo, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biological prognostic factors for early stage completely resected non-small cell lung cancer.

M. Tonato, V. Ludovini, V. Gregorc, 2000, Journal of surgical oncology.

A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.

V. Ludovini, P. Ulivi, D. Santini, 2021, Translational lung cancer research.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of the National Cancer Institute.

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report

L. Crinò, V. Ludovini, E. Valtorta, 2015, Ecancermedicalscience.

Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.

M. Tonato, G. Ceresoli, I. Floriani, 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

L. Crinò, P. Floridi, R. Chiari, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

R. Chiari, V. Ludovini, G. Metro, 2018, Clinical Drug Investigation.

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

F. Cappuzzo, F. Hirsch, P. Bunn, 2005, British Journal of Cancer.

Liquid Biopsy in Early Breast Cancer: A Preliminary Report

V. Ludovini, V. Talesa, D. Messineo, 2019, Annals of Clinical Oncology.

CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study

L. Crinò, V. Ludovini, F. Barberini, 2009, BMC Cancer.

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

G. Minuti, L. Crinò, M. Canale, 2022, Translational oncology.

DKC1 gene mutations in human sporadic cancer.

L. Crinò, L. Montanaro, D. Treré, 2013, Histology and histopathology.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2016, Clinical Drug Investigation.

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy

F. Roila, R. Chiari, V. Ludovini, 2021, Genes.

Epigenetic control of INSL4 promotes cell growth and invasiveness in Non-Small-Cell Lung Cancer

V. Ludovini, E. Puxeddu, G. Servillo, 2020 .

Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models

E. Petricoin, L. Crinò, V. Ludovini, 2021, International journal of molecular sciences.

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

R. Chiari, V. Ludovini, G. Metro, 2018, Lung cancer.

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

L. Crinò, M. Tonato, I. Floriani, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Robustness of complex feedback systems: application to oncological biochemical networks

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2013, Int. J. Control.

Corrigendum to "Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology" (Biotechnol Adv 30 (2012) 142-153)

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2013 .

Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2012, Biotechnology advances.

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

G. Giaccone, E. Petricoin, L. Crinò, 2021, Journal for ImmunoTherapy of Cancer.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

M. Varella‐Garcia, L. Crinò, R. Chiari, 2013, Cancer Chemotherapy and Pharmacology.

Dyskerin and TERC expression may condition survival in lung cancer patients

L. Crinò, L. Montanaro, D. Treré, 2015, Oncotarget.

Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma.

V. Ludovini, F. Bianconi, J. Vannucci, 2017, Interactive cardiovascular and thoracic surgery.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications

R. Chiari, V. Ludovini, G. Mondanelli, 2018, Virchows Archiv.

INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer

V. Ludovini, E. Puxeddu, G. Servillo, 2021, Journal of Cancer.

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

M. Sassi, F. Roila, V. Ludovini, 2021, Genes.

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren’s syndrome

L. Crinò, V. Ludovini, R. Gerli, 2011, Lupus.

Plasma DNA, Microsatellite Alterations, and p53 Tumor Mutations Are Associated with Disease-Free Survival in Radically Resected Non-small Cell Lung Cancer Patients: A Study of the Perugia Multidisciplinary Team for Thoracic Oncology

L. Crinò, M. Tonato, I. Floriani, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

L. Landi, L. Crinò, M. Canale, 2020, Journal of clinical medicine.

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.

S. Pignata, V. Ludovini, G. Scambia, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

L. Crinò, R. Chiari, C. Bennati, 2014, Clinical lung cancer.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Fortunato Bianconi, Elisa Baldelli, Vienna Ludovini, 2017, Oncotarget.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

A. Chella, L. Landi, C. Tibaldi, 2014, British Journal of Cancer.

Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties

H. Schünemann, F. Mancini, F. Moretti, 2008, Journal of Molecular Medicine.

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice

M. Papotti, S. Novello, A. Sapino, 2021, Journal of Clinical Pathology.

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

L. Crinò, C. Ficorella, R. Chiari, 2019, Clinical and Translational Oncology.

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

L. Crinò, R. Chiari, C. Bennati, 2012, Lung cancer.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

L. Crinò, F. Bianconi, R. Chiari, 2012, Cancer Chemotherapy and Pharmacology.

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib

M. Hidalgo, S. Marsh, S. Baker, 2008, Clinical pharmacology and therapeutics.

Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool

F. Roila, R. Chiari, V. Ludovini, 2020, Frontiers in Immunology.

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

M. Varella‐Garcia, L. Crinò, V. Ludovini, 2015, American journal of clinical oncology.

Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.

M. Tonato, I. Floriani, V. Ludovini, 2003, Lung cancer.

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

M. Hidalgo, J. Verweij, R. Ingersoll, 2006, Journal of the National Cancer Institute.

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer

L. Crinò, M. Canale, E. Petracci, 2019, Journal of clinical medicine.

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

F. Cappuzzo, A. Cancellieri, L. Crinò, 2004, Journal of the National Cancer Institute.

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.

L. Landi, A. D’Incecco, G. Fontanini, 2014, Clinical colorectal cancer.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

Genome-wide expression of the residual lung reacting to experimental Pneumonectomy

F. Venuta, M. Anile, V. Napolioni, 2021, BMC genomics.

Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients

M. Tonato, V. Ludovini, M. Colozza, 2003, Breast Cancer Research and Treatment.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

L. Crinò, R. Chiari, C. Bennati, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC)

L. Crinò, R. Chiari, V. Ludovini, 2013, Virchows Archiv.

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

L. Crinò, V. Ludovini, M. Colozza, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Large Cell Neuroendocrine Carcinoma Transformation and EGFR‐T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR‐TKIs in Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2017, Mayo Clinic proceedings.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine

E. Petricoin, M. Schabath, L. Crinò, 2015, PROTEOMICS - Clinical Applications.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

A. Marchetti, F. Buttitta, A. Chella, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

L. Crinò, V. Ludovini, F. Bianconi, 2014, American journal of clinical oncology.

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

S Gori, L. Crinò, I. Floriani, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.

M. Tonato, I. Floriani, V. Ludovini, 2004, Lung cancer.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

E. Petricoin, L. Liotta, M. Schabath, 2015, Oncotarget.

Unique case of sporadic multiple gastro intestinal stromal tumour

V. Ludovini, L. Graziosi, A. Donini, 2015, International journal of surgery case reports.

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature

F. Roila, V. Ludovini, G. Metro, 2020, Oncology and Therapy.

Biological prognostic factors for early stage completely resected non–small cell lung cancer

Vienna Ludovini, Vanesa Gregorc, Lucio Cagini, 2000 .

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature

F. Roila, V. Ludovini, G. Metro, 2022, Oncology and Therapy.

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients

F. Roila, R. Chiari, V. Ludovini, 2021, Genes.

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

E. Petricoin, J. Carpten, L. Crinò, 2021, Genes.

Interobserver Reproducibility of Immunohistochemical Her-2/Neu Evaluation in Human Breast Cancer: The Real-World Experience

S. Ménard, P. Querzoli, A. Paradiso, 2004, The International journal of biological markers.

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR

L. Crinò, F. Roila, A. Delmonte, 2020, Diagnostics.

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

D. Radisky, F. Modugno, P. Visca, 2014, Oncotarget.

Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer

V. Torri, F. Cappuzzo, L. Crinò, 2004, Clinical Cancer Research.

Salvage chemotherapy in metastatic breast cancer: An experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin

M. Tonato, V. Ludovini, M. Colozza, 2005, Breast Cancer Research and Treatment.

Biological Markers and DNA Flow Cytometric Analysis in Radically Resected Patients with Non-Small Cell Lung Cancer. A Study of the Perugia Multidisciplinary Team for Thoracic Tumors

L. Crinò, M. Tonato, I. Floriani, 2008, Tumori.

Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.

V. Ludovini, A. Cavaliere, A. Sidoni, 1996, Cytometry.

A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report

P. Radice, V. Ludovini, E. Minenza, 2023, Frontiers in Oncology.

Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study

F. Roila, V. Ludovini, F. Bianconi, 2020, Genes.

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

L. Crinò, M. Tonato, I. Floriani, 2017, BMC Cancer.

Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

D. Amadori, L. Crinò, D. Calistri, 2016 .

miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy.

L. Landi, F. Cappuzzo, L. Crinò, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.

E. Felip, D. Planchard, V. Ludovini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.

F. Roila, V. Ludovini, B. Di Girolamo, 2022, Journal of chemotherapy.

BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors

V. de Giorgi, M. Mandalà, D. Massi, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer.

L. Crinò, G. Ceresoli, V. Ludovini, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

R. Chiari, V. Ludovini, G. Metro, 2018, Journal of Thoracic Oncology.

KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

R. Chiari, V. Ludovini, D. Giannarelli, 2018, Molecular and clinical oncology.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

E. Petricoin, P. Valigi, L. Crinò, 2015, BMC Systems Biology.